1 / 25

Chapter 21

Chapter 21. Drugs for Parkinson’s Disease. Parkinson’s Disease. Parkinson’s disease (PD) is a neurodegenerative disorder of the extrapyramidal system associated with disruption of neurotransmission in the striatum Characterized by dyskinesias and akinesia

ruby-tyler
Télécharger la présentation

Chapter 21

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chapter 21 Drugs for Parkinson’s Disease

  2. Parkinson’s Disease • Parkinson’s disease (PD) is a neurodegenerative disorder of the extrapyramidal system associated with disruption of neurotransmission in the striatum • Characterized by dyskinesias and akinesia • Proper function of the striatum requires a balance between the neurotransmitters dopamine and acetylcholine (ACh) • Imbalance between dopamine and ACh results from degeneration of the neurons that supply dopamine to the striatum.

  3. Parkinson’s Disease • Affects more than 1 million Americans • Second only to Alzheimer’s disease as the most common degenerative disease of neurons • Symptoms generally appear in middle age and progress • No cure for motor symptoms • Drug therapy can maintain functional mobility for years (prolongs/improves quality of life).

  4. Cardinal Symptoms of PD • Dyskinesias • Tremor at rest • Rigidity • Postural instability • Bradykinesia (slowed movement) • Tremor • In addition to motor symptoms • Autonomic disturbances • Depression • Psychosis and dementia

  5. Dopamine/ACh Imbalance in Striatum • Imbalance results from degeneration of the neurons that supply dopamine to the striatum. • Without adequate dopamine, ACh causes excessive stimulation of GABA-releasing neurons. • Overactivity of GABA neurons contributes to the motor symptoms of PD. • Uncertain of cause of degeneration—may be alpha-synuclein.

  6. Fig. 21-1. A model of neurotransmission in the healthy striatum and parkinsonian striatum.

  7. Parkinson’s Disease • Therapeutic goals • Ideal treatment (reverse neuronal degeneration or prevent further degeneration) does not exist. • Goal is to improve patient’s ability to carry out activities of daily life. • Drug selection and dosages are determined by extent to which PD interferes with work, dressing, eating, bathing, and other activities of daily living.

  8. Drug Therapy for Parkinson’s Disease • Two major categories • Dopaminergic agents • By far the most commonly used drugs for PD • Promote activation of dopamine receptors • Levodopa (Dopar) • Anticholinergic agents • Prevent activation of cholinergic receptors • Benztropine (Cogentin)

  9. Drug Therapy for Parkinson’s Disease • Levodopa (drug holidays recommended) • Levodopa/carbidopa • Dopamine agonists • Pramipexole (Mirapex) • Entacapone (Comtan) • Amantadine (Symmetrel) • Selegiline (Eldepryl, Carbex)

  10. Dopaminergic Agents • Mechanisms of action • Levodopa: promotes dopamine synthesis • Dopamine agonists: stimulate dopamine receptors directly • Selegiline: inhibits dopamine breakdown • Amantadine: promotes dopamine release • COMT inhibitors: enhance effects of levodopa by blocking its degradation

  11. Drug Selection: Initial Treatment • Mild symptoms: MAO-B inhibitor • Selegiline or rasagiline • More severe symptoms: levodopa or a dopamine agonist • Levodopa more effective than dopamine agonists, but long-term use carries a higher risk for disabling dyskinesias • Management of motor fluctuations • “Off” times (can be reduced with dopamine agonists, COMT inhibitors, and MAO-B inhibitors) • Drug-induced dyskinesias

  12. Fig. 21-2. Steps leading to alteration of CNS function by levodopa.

  13. Fig. 21-3. Conversion of levodopa to dopamine.

  14. Levodopa • Only given in combination with carbidopa or carbidopa/entacapone • Highly effective, but benefits diminish over time • Orally administered, rapid absorption from small intestine • Food delays absorption. • Neutral amino acids compete with levodopa for intestinal absorption and for transport across blood-brain barrier. • High-protein foods will reduce therapeutic effects.

  15. Levodopa • Adverse effects • Nausea and vomiting • Dyskinesias • Cardiovascular effects • Psychosis • May darken sweat and urine • Can activate malignant melanoma • Drug holidays • Drug interactions: first-generation antipsychotics, MAOIs, anticholinergics, pyridoxine • Food interactions: protein and vitamins with pyridoxine

  16. Carbidopa • Advantages • No adverse effects of its own • Increases available levodopa in the CNS and allows for 75% decrease in levodopa dosage; therefore, reduces cardiovascular and GI adverse effects • Effects come mainly from levodopa when given in combination. • Levodopa/carbidopa (Sinemet, Paracopa) • Carbidopa alone (Lodosyn)

  17. Fig. 21-4. Fate of levodopa in the presence and absence of carbidopa.

  18. Dopamine Agonists • First-line drugs for PD • Direct activation of dopamine receptors in striatum • Comparison with levodopa • Less effective than levodopa • Not dependent on enzymatic conversion to be active • Do not compete with dietary proteins • Lower incidence of response failure and less likely to cause dyskinesias • Two types of dopamine agonists • Derivatives of ergot • Nonergot derivatives

  19. Nonergot Dopamine Agonists • Pramipexole (Mirapex) • Used alone in early PD and with levodopa in advancing PD • Maximal benefits take several weeks to develop. • Adverse effects • Monotherapy – nausea, dizziness, daytime somnolence, insomnia, constipation, weakness, and hallucinations • Combined – orthostatic hypotension and dyskinesias and increase in hallucinations • Rare instances of pathologic gambling and other compulsive self-rewarding behaviors

  20. COMT Inhibitors • Inhibit metabolism of levodopa in the periphery • No direct therapeutic effects of their own • Two COMT inhibitors available • Entacapone (safer and more effective) • Tolcapone

  21. Entacapone • Selective, reversible inhibitor of COMT • Only for use with levodopa • Inhibits metabolism of levodopa in the intestines and peripheral tissues • Prolongs time that levodopa is available to the brain • Increases levodopa availability by inhibiting COMT, which decreases production of levodopa metabolites that compete with levodopa for transport • Adverse effects: from increasing levodopa levels

  22. Levodopa/Carbidopa/Entacapone • Fixed-dose combinations sold as Stalevo • More convenient than taking separate doses • Costs a little less • Disadvantage • Available only in immediate-release tablets • Available in only three strengths

  23. MAO-B Inhibitors • Considered second- and third-line drugs for treatment of PD • Combination with levodopa – can reduce the wearing-off effect • Selegiline

  24. Selegiline (Eldepryl, Zelapar) • Monotherapy or used with levodopa • Modest improvement in motor function • Causes selective, irreversible inhibition of type B monoamine oxidase (MAO-B) • Can suppress destruction of dopamine derived from levodopa and prolong the effects of levodopa • Adverse effects • Monotherapy: insomnia • Drug interactions: levodopa

  25. Nonmotor Symptoms and Their Management • 90% of patients develop nonmotor symptoms (autonomic disturbances, depression, dementia, and psychosis). • Depression • Amitriptyline: only effective drug • TCA • Anticholinergic effects that can exacerbate dementia • Antiadrenergic effects that can exacerbate hypotension

More Related